Results of a study involving the addition of Bortezomib to the Hyper-CVAD regimen for first line treatment of mantle cell lymphoma.
Results of a study involving the addition of Bortezomib to the Hyper-CVAD regimen for first line treatment of mantle cell lymphoma.